Compare CRCT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRCT | REPL |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.6M | 692.8M |
| IPO Year | 2021 | 2018 |
| Metric | CRCT | REPL |
|---|---|---|
| Price | $4.08 | $7.08 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $3.50 | ★ $11.13 |
| AVG Volume (30 Days) | 600.2K | ★ 1.2M |
| Earning Date | 03-03-2026 | 02-03-2026 |
| Dividend Yield | ★ 23.00% | N/A |
| EPS Growth | ★ 20.69 | 5.25 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $708,780,000.00 | N/A |
| Revenue This Year | $0.08 | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | $11.81 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.92 | $2.68 |
| 52 Week High | $7.33 | $13.24 |
| Indicator | CRCT | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 45.02 |
| Support Level | $3.92 | $6.89 |
| Resistance Level | $4.57 | $8.82 |
| Average True Range (ATR) | 0.12 | 0.55 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 49.28 | 26.73 |
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.